Price movement over the last 24 hours
Adaptive Biotechnologies Corp vs Super Micro Computer Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while Super Micro Computer Inc trades at $27.03 (market cap $16.98B). The key difference: Super Micro Computer Inc is far larger — about 5.1× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Super Micro Computer Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | SMCI | |
|---|---|---|
Market Cap | $3.33B | $16.98B |
Sector | Health | Technology |
52-Week High | $22.37 | $60.71 |
52-Week Low | $10.24 | $20.53 |
Enterprise Value | $3.19B | $24.50B |
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Super Micro Computer (SMCI) trades at $27.19, down 0.11% with bearish technical signals. The stock faces headwinds from a Taiwan probe into alleged AI chip smuggling, contributing to recent volatility. Fundamentally, SMCI shows strong revenue growth with $22B in 2025 and $33.7B projected for 2026, though profit margins compressed from 4.77% to 3.7%. Valuation appears attractive with P/E of 14.31 and P/S of 0.54, while recent earnings beat expectations in two of the last three quarters.
The outlook remains cautious due to regulatory risks and negative technical momentum. Analyst consensus is mixed with 36% buy ratings and a $36.43 price target suggesting 34% upside. Key risks include the ongoing Taiwan investigation, competitive pressures in AI infrastructure, and cash flow volatility with projected negative operating cash flow in 2026. The stock presents a value opportunity but requires careful risk management.
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →